Masimo Corporation (MASI) CEO, Chairman and Founder to Ring the NASDAQ Stock Market Opening Bell

August 6, 2008
Joe Kiani, CEO, Chairman and Founder of Masimo Corporation (MASI), will
preside over the opening bell.

NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio

Thursday, August 7, 2008 at 9:30 a.m. ET

The opening bell is available from 9:20 a.m. to 9:35 a.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal, and on Waterfront fiber 1623.


A live webcast of the NASDAQ Opening Bell will be available at:


To obtain a hi-resolution photograph of the Market Open, please go to and click on the market open of your choice.

About Masimo:

Masimo (Nasdaq:MASI) develops innovative monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. Masimo's IPO was one of the most successful IPOs of 2007 and 2008, and was the top medical device IPO over the same period.

Masimo's success comes from innovation. Recently, Masimo introduced its latest breakthrough technology -- the first-and-only FDA-cleared technology that noninvasively and continuously measures total hemoglobin-without a painful needle stick and invasive blood draw. Masimo noninvasive total hemoglobin monitoring delivers significant benefits to patients and healthcare professionals by enabling earlier and better clinical decision-making, improved patient safety, and reduced costs

In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, a breakthrough noninvasive blood constituent monitoring platform that measures many blood constituents that previously required invasive procedures. Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(tm)), oxygen content (SpOC(tm)), carboxyhemoglobin (SpCO(r)), methemoglobin (SpMet(r)), and PVI(tm), in addition to oxyhemoglobin (SpO2), perfusion index (PI) and pulse rate.

This news release was distributed by PrimeNewswire,


Founded in 1989, Masimo is focused on its mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at

Dana Banks
(949) 309-7759

NASDAQ MarketSite:
Jolene Libretto